Open Clinical Trials for Breast Cancer in Canada

Use our blog on Understanding Common Research Terms as a guide for some of the terms we reference.

December 2025

Early-Stage

HR positive

Title: An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

> **Summary:** The goal of this study is to see if camizestrant improves outcomes compared to the standard adjuvant hormone therapy for people with ER positive breast cancer with high risk for recurrence.
>
> **Eligibility:** Patients with high risk of recurrence who have completed surgery with or without radiation and chemotherapy
>
> **Locations:** Calgary, AB; Edmonton, AB; Kelowna, BC; North Vancouver, BC; Barrie, ON; Sudbury, ON; Kingston, ON; Thunder Bay, ON; Chicoutimi, QC; Lévis, QC; Montreal, QC; Québec, QC; Saskatoon, SK
>
> Learn more

Title: A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+, HER2-, Early Breast Cancer With High Risk of Recurrence

Summary: The goal of this study is to evaluate the effectiveness of elacestrant compared to standard hormone therapy in people with node-positive, ER positive breast cancer with a high risk of recurrence.

Eligibility: Patients with high risk of recurrence, lymph node positive

Locations: Surrey, BC; Vancouver, BC; Barrie, ON; London, ON; Toronto, ON; Montreal, QC; Saint-Jérôme, QC; Québec, QC

Learn more

Title: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Summary: The goal of this study is to determine whether adjuvant chemotherapy added to ovarian function suppression (OFS) plus hormone therapy is more effective than OFS plus hormone therapy in patients with ER positive breast cancer who are premenopausal and have an Oncotype score of less than 25.

Eligibility: Premenopausal patients with an Oncotype score of less than or equal to 25

Locations: Barrie, ON; Kitchener, ON; London, ON; Oakville, ON; Oshawa, ON; Toronto, ON; Montreal, QC; Québec, QC; Sherbrooke, QC

Learn more

Triple Negative

Title: Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Summary: The goal of this study is to compare the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab to treatment of physician's choice in people with triple negative disease who received neoadjuvant therapy and did not achieve a pathological complete response (meaning patient still had cancer present at the time of surgery).

Eligibility: Had neoadjuvant treatment followed by surgery; had residual disease (non-pCR) at the time of surgery

Locations: Edmonton, AB; Vancouver, BC; Winnipeg, MB; Halifax, NS; Newmarket, ON; Ottawa, ON; Toronto, ON; Greenfield Park, QC; Montreal, QC; Rimouski, QC; Trois-Rivières, QC

Learn more

Title: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Summary: The goal of this study is to compare the effect of pembrolizumab to observation for the treatment of triple negative breast cancer in people who achieved a pathologic complete response (meaning they had no cancer remaining at the time of surgery) after neoadjuvant

therapy. This may help researchers determine if observation will result in the same risk of cancer coming back.

Eligibility: Had neoadjuvant treatment followed by surgery; had no residual disease (pCR) at the time of surgery

Locations: Kelowna, BC; Vancouver, BC; Saint John, NB; Cambridge, ON; Kingston, ON; London, ON; Ottawa, ON; Toronto, ON; Québec, QC; Québec, QC; Regina, SK; Saskatoon, SK

Learn more

Surgery and Radiation

Title: Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy

Summary: This study aims to determine whether whole breast radiation can be safely omitted for patients who have a pathologic complete response (meaning they had no cancer remaining at the time of surgery) after neoadjuvant chemotherapy and breast-conserving surgery.

Eligibility: Node negative disease; previous neoadjuvant treatment with no residual disease (pCR) at the time of surgery

Locations: Prince George, BC; Barrie, ON; Hamilton, ON; Kingston, ON; Thunder Bay, ON; Toronto, ON; Montreal, QC; Québec, QC; Trois-Rivières, QC

Learn more

Title: Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)

Summary: The goal of this study is to determine the effect of an intraoperative intravenous lidocaine infusion on reducing the development of persistent pain 3 months after breast cancer surgery.

Eligibility: Undergoing a unilateral or bilateral lumpectomy or mastectomy

Locations: Calgary, AB; Edmonton, AB; St. John's, NL; Halifax, NS; Hamilton, ON; North York, ON; Ottawa, ON; Thunder Bay, ON; Toronto, ON; Montreal, QC

Learn more

Title: De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Summary: The goal of this study is to evaluation whether lumpectomy and hormone therapy results in similar outcomes compared to lumpectomy with breast radiation and hormone therapy.

Eligibility: Must have undergone a lumpectomy with an Oncotype score of less than or equal to 18

Locations: Saint John, NB; Kingston, ON; Toronto, ON; Montreal, QC; Regina, SK; Saskatoon, SK

Learn more

Metastatic

HR positive

Title: Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Summary: The goal of this study is to understand how ER positive metastatic breast cancer becomes resistant to CDK4/6 inhibitors and to look at DNA changes and other biomarkers in the blood to help identify and track resistance as it develops.

Phase: 2

Eligibility: Must have had disease progression on first line CDK4/6 inhibitor plus hormone therapy

Locations: Calgary, AB; Kelowna, BC; Vancouver, BC; Halifax, NS; Hamilton, ON; Kingston, ON; Ottawa, ON; Toronto, ON; Montreal, QC

Learn more

Title: Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Summary: The goal of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (for example, palbociclib, ribociclib or abemaciclib with letrozole) in people with HR positive, HER2 negative metastatic disease.

Phase: 3

Eligibility: Previously untreated with any systemic anticancer therapy for locally advanced or metastatic disease

Locations: Calgary, AB; Edmonton, AB; Fredericton, NB; Toronto, ON; Montreal, QC

Learn more

Title: A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Summary: The goal of this study is to evaluate the efficacy and safety of the combination of inavolisib plus a CDK4/6 inhibitor and letrozole compared to a placebo plus CDK4/6 inhibitor and letrozole.

Phase: 3

Eligibility: Previously untreated with systemic therapy for locally advanced or metastatic disease

Locations: Winnipeg, MB; Moncton, NB; Ottawa, ON; Sault Ste. Marie, ON; Toronto, ON; Montreal, QC, Saint-Jérôme, QC

Learn more

Title: A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Summary: The goal of this study is to evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with investigator's choice of a CDK4/6 inhibitor in patients who have developed resistance to adjuvant hormone therapy.

Phase: 3

Eligibility: Confirmed ESR1 mutation; resistance to prior adjuvant hormone therapy; no prior systemic therapy for advanced disease

Locations: Edmonton, AB; Barrie, ON; Mississauga, ON; Oshawa, ON; Thunder Bay, ON; Toronto, ON; Chicoutimi, QC; Lévis, QC; Montreal, QC; Québec, QC; Saint-Jérôme, QC; Trois-Rivières, QC

Learn more

Title: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Summary: The goal of this study is to evaluate the safety and efficacy of capivasertib plus CDK4/6 inhibitors plus fulvestrant compared to CDK4/6 inhibitors and fulvestrant in HR positive, HER2 negative metastatic breast cancer.

Phase: 3

Eligibility: Able to receive fulvestrant and a CDK4/6 inhibitor

Locations: Abbotsford, BC; Kelowna, BC; Winnipeg, MB; Moncton, NB; Halifax, NS; Brampton, ON; Ottawa, ON; Toronto, ON; Sherbrooke, QC; Chicoutimi, QC; Montreal, QC

Learn more

HER2 positive / HER2-Low

Title: Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Summary: The goal of this study is to see if patritumab deruxtecan (MK-1022) can treat HER2 positive metastatic breast cancer as well as how people respond and tolerate it.

Phase: 1/2

Eligibility: Has received between 2 to 5 prior lines of anti-HER2 therapy, with certain study arms also requiring prior progression on trastuzumab deruxtecan (T-DXd)

Locations: Kingston, ON; Toronto, ON; Montreal, QC

Learn more

Title: A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

> **Summary:** The goal of this study is to evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab and rHuPH20 injection for subcutaneous use) compared with a placebo in combination with Phesgo.
>
> **Phase:** 3
>
> **Eligibility:** Patients with previously untreated HER2 positive metastatic breast cancer; confirmed PIK3CA-mutation
>
> **Locations:** Calgary, AB; Moncton, NB; St. John's, NL; Toronto, ON; Montreal, QC; Québec, QC; Regina, SK
>
> Learn more

Title: A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

> **Summary:** The goal of this study is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice of chemotherapy in terms of progression-free survival (meaning how long a patient lives without their cancer getting worse).
>
> **Phase:** 3
>
> **Eligibility:** HER2-low expression (IHC 1+ or IHC 2+/ISH-); never previously reported as HER2 positive; must have had disease progression on hormone therapy plus CDK4/6 inhibitor or at least 2 previous lines of hormone therapy with or without targeted therapy
>
> **Locations:** Winnipeg, MB; Brampton, ON; Toronto, ON; Montreal, QC; Sherbrooke, QC
>
> Learn more

Triple Negative

Title: A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

> **Summary:** The goal of this study is to assess the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice of chemotherapy in combination with pembrolizumab in patients with PD-L1 positive metastatic TNBC.
>
> **Phase:** 3
>
> **Eligibility:** PD-L1 positive; no prior chemotherapy or other systemic anti-cancer therapy for metastatic breast cancer

Locations: Barrie, ON; Hamilton, ON; Toronto, ON; Greenfield Park, QC; Montreal, QC; Québec, QC; Regina, SK; Saskatoon, SK

Learn more